Wolfe Research initiated coverage of Merck (MRK) with a Peer Perform rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- PDS Biotechnology price target lowered to $4.50 from $7 at Alliance Global Partners
- Merck enters exclusive global license for LM-299
- Zentalis appoints Eastland as CEO, Bruns as CMO, Myers as Chairperson
- Ginkgo Bioworks receives $9M milestone payment from Merck partnership
- Merck and AstraZeneca announce results of Koselugo in neurofibromatosis trial